OA10134A - Therapeutic compounds derived from the neem tree - Google Patents

Therapeutic compounds derived from the neem tree Download PDF

Info

Publication number: OA10134A
Authority: OA; OAPI
Prior art keywords: purified; treatment; cells; extract; need
Prior art date: 1992-09-11

Application number

OA60623A

Other languages

English (en)

Inventor

Udeinya Iroka

Original Assignee

Neem Pharmaco

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-11

Filing date

1995-03-10

Publication date

1996-12-18

1995-03-10 Application filed by Neem Pharmaco filed Critical Neem Pharmaco

1996-12-18 Publication of OA10134A publication Critical patent/OA10134A/en

Links

235000013500 Melia azadirachta Nutrition 0.000 title claims abstract description 42
230000001225 therapeutic effect Effects 0.000 title claims description 14
150000001875 compounds Chemical class 0.000 title description 23
240000005343 Azadirachta indica Species 0.000 title 1
239000000284 extract Substances 0.000 claims abstract description 60
244000237986 Melia azadirachta Species 0.000 claims abstract description 41
208000015181 infectious disease Diseases 0.000 claims abstract description 19
238000000034 method Methods 0.000 claims description 27
239000002904 solvent Substances 0.000 claims description 16
238000004128 high performance liquid chromatography Methods 0.000 claims description 15
208000036142 Viral infection Diseases 0.000 claims description 9
230000009385 viral infection Effects 0.000 claims description 9
238000001035 drying Methods 0.000 claims description 3
241000224016 Plasmodium Species 0.000 claims description 2
239000002244 precipitate Substances 0.000 claims description 2
238000002791 soaking Methods 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 7
208000037819 metastatic cancer Diseases 0.000 claims 4
208000011575 metastatic malignant neoplasm Diseases 0.000 claims 4
210000004027 cell Anatomy 0.000 abstract description 104
206010028980 Neoplasm Diseases 0.000 abstract description 29
201000011510 cancer Diseases 0.000 abstract description 28
244000045947 parasite Species 0.000 abstract description 23
238000000605 extraction Methods 0.000 abstract description 18
241000700605 Viruses Species 0.000 abstract description 11
230000001568 sexual effect Effects 0.000 abstract description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
201000010099 disease Diseases 0.000 abstract description 9
201000004792 malaria Diseases 0.000 abstract description 9
230000002458 infectious effect Effects 0.000 abstract description 6
210000002889 endothelial cell Anatomy 0.000 abstract description 4
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
239000000047 product Substances 0.000 description 20
230000000181 anti-adherent effect Effects 0.000 description 17
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
238000003556 assay Methods 0.000 description 15
230000000694 effects Effects 0.000 description 15
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
239000002609 medium Substances 0.000 description 14
239000000203 mixture Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
230000008569 process Effects 0.000 description 9
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
229940082880 azadirachta indica flower extract Drugs 0.000 description 8
239000007788 liquid Substances 0.000 description 8
239000000843 powder Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
239000000853 adhesive Substances 0.000 description 7
230000000840 anti-viral effect Effects 0.000 description 7
238000011161 development Methods 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
241000255925 Diptera Species 0.000 description 6
241000725303 Human immunodeficiency virus Species 0.000 description 6
241000223960 Plasmodium falciparum Species 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
238000005194 fractionation Methods 0.000 description 6
239000011521 glass Substances 0.000 description 6
238000001228 spectrum Methods 0.000 description 6
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 5
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
229960000583 acetic acid Drugs 0.000 description 5
238000002832 anti-viral assay Methods 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 5
229960003677 chloroquine Drugs 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
208000003747 lymphoid leukemia Diseases 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
239000002245 particle Substances 0.000 description 5
201000000239 Phlebotomus fever Diseases 0.000 description 4
206010037660 Pyrexia Diseases 0.000 description 4
238000000944 Soxhlet extraction Methods 0.000 description 4
241000710772 Yellow fever virus Species 0.000 description 4
235000011054 acetic acid Nutrition 0.000 description 4
229910002092 carbon dioxide Inorganic materials 0.000 description 4
229940063774 carbon dioxide 5 % Drugs 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
238000005534 hematocrit Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
210000003936 merozoite Anatomy 0.000 description 4
238000000386 microscopy Methods 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
229940051021 yellow-fever virus Drugs 0.000 description 4
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
208000009182 Parasitemia Diseases 0.000 description 3
208000030852 Parasitic disease Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
239000001569 carbon dioxide Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000007789 gas Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
210000003701 histiocyte Anatomy 0.000 description 3
238000000099 in vitro assay Methods 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
-1 octadecylsilyl Chemical group 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
238000000746 purification Methods 0.000 description 3
201000006845 reticulosarcoma Diseases 0.000 description 3
208000029922 reticulum cell sarcoma Diseases 0.000 description 3
230000001445 schizonticidal effect Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
210000003606 umbilical vein Anatomy 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
230000005526 G1 to G0 transition Effects 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
241001135555 Sandfly fever Sicilian virus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000000078 anti-malarial effect Effects 0.000 description 2
239000003430 antimalarial agent Substances 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
238000011068 loading method Methods 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
239000012046 mixed solvent Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000002018 neem oil Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
238000003359 percent control normalization Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
210000001563 schizont Anatomy 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
210000003046 sporozoite Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000829 suppository Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000001291 vacuum drying Methods 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
239000003643 water by type Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
JMBKXUYCBVKSSY-DOTOQJQBSA-N (4as,10as)-6,7-dihydroxy-1,1,4a-trimethyl-3,4,10,10a-tetrahydro-2h-phenanthren-9-one Chemical compound OC1=C(O)C=C2[C@@]3(C)CCCC(C)(C)[C@@H]3CC(=O)C2=C1 JMBKXUYCBVKSSY-DOTOQJQBSA-N 0.000 description 1
OIYMSAOAFKGCMV-UHFFFAOYSA-N 7-acetylneotrichilenone Natural products CC(=O)OC1CC2C(C)(C)CC=CC2(C)C3CCC4(C)C(CCC4C13C)c5cocc5 OIYMSAOAFKGCMV-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
241000557821 Azadirachta Species 0.000 description 1
241001639790 Berghia Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
241000257465 Echinoidea Species 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
HPXDQBYDTJMQHA-UHFFFAOYSA-N Gedunin Natural products CC1CC2C3(C)C=CC(=O)C(C)(C)C3CC(OC(=O)C)C2(C)C45OC4C(=O)OC(C15)c6cocc6 HPXDQBYDTJMQHA-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010061201 Helminthic infection Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000603223 Homo sapiens Nischarin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101100015375 Mus musculus Gnaz gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
102100038995 Nischarin Human genes 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010037075 Protozoal infections Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
241001591024 Samea Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CESGKXMBHGUQTB-VONOSFMSSA-N [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(OC(=O)CCCCCCCCCCCCC)C(C)(C)[C@H]3[C@@H]21 CESGKXMBHGUQTB-VONOSFMSSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000012675 alcoholic extract Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000002927 anti-mitotic effect Effects 0.000 description 1
230000001355 anti-mycobacterial effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000003926 antimycobacterial agent Substances 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
230000004712 cancer cell adhesion Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000003352 cell adhesion assay Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000007123 defense Effects 0.000 description 1
239000010432 diamond Substances 0.000 description 1
LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical class CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
230000000646 gametocidal effect Effects 0.000 description 1
YJXDGWUNRYLINJ-BHAPSIHVSA-N gedunin Chemical compound C=1([C@H]2[C@]3(C)CC[C@@H]4[C@@]5(C)C=CC(=O)C(C)(C)[C@@H]5C[C@H]([C@]4([C@]33O[C@@H]3C(=O)O2)C)OC(=O)C)C=COC=1 YJXDGWUNRYLINJ-BHAPSIHVSA-N 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000013210 hematogenous Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002129 infrared reflectance spectroscopy Methods 0.000 description 1
239000000077 insect repellent Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
JMBKXUYCBVKSSY-UHFFFAOYSA-N nimbidiol Natural products OC1=C(O)C=C2C3(C)CCCC(C)(C)C3CC(=O)C2=C1 JMBKXUYCBVKSSY-UHFFFAOYSA-N 0.000 description 1
JZIQWNPPBKFOPT-LSYMHUITSA-N nimbolide Chemical compound C=1([C@@H]2C[C@H]3O[C@H]4[C@](C3=C2C)(C)[C@@H]([C@@]2(C)C(=O)C=C[C@@]3(C)C(=O)O[C@@H]4[C@H]23)CC(=O)OC)C=COC=1 JZIQWNPPBKFOPT-LSYMHUITSA-N 0.000 description 1
WKFCTWCVHKIFBR-UHFFFAOYSA-N nimbolide Natural products COC(=O)CC1C2(C)C(OC3CC(C(=C23)C)c4occc4)C5OC(=O)C6(C)C=CC(=O)C1(C)C56 WKFCTWCVHKIFBR-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229940062097 nitrogen 90 % Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000014207 opsonization Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000005059 placental tissue Anatomy 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000005180 public health Effects 0.000 description 1
239000012264 purified product Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000005871 repellent Substances 0.000 description 1
230000002940 repellent Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
150000003534 tetranortriterpenoids Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
210000003812 trophozoite Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003501 vero cell Anatomy 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Mycology (AREA)
Medical Informatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Botany (AREA)
Communicable Diseases (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

OA60623A 1992-09-11 1995-03-10 Therapeutic compounds derived from the neem tree OA10134A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/944,201 US5370873A (en)	1992-09-11	1992-09-11	Therapeutic compounds derived from the neem tree

Publications (1)

Publication Number	Publication Date
OA10134A true OA10134A (en)	1996-12-18

Family

ID=25480990

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA60623A OA10134A (en)	1992-09-11	1995-03-10	Therapeutic compounds derived from the neem tree

Country Status (9)

Country	Link
US (1)	US5370873A (fr)
EP (1)	EP0671925A4 (fr)
JP (1)	JPH08504403A (fr)
KR (1)	KR950703348A (fr)
AU (1)	AU4844093A (fr)
BR (1)	BR9307044A (fr)
CA (1)	CA2144320A1 (fr)
OA (1)	OA10134A (fr)
WO (1)	WO1994017815A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5397571A (en) *	1993-03-25	1995-03-14	W. R. Grace & Co.-Conn.	Co-extraction of azadirachtin and neem oil
US5871749A (en) *	1993-07-27	1999-02-16	Csl Limited	Therapeutic treatment of H. pylori associated gastroduodenal disease
WO1997045349A1 (fr) *	1996-05-24	1997-12-04	Marel Hf.	Dispositif de manutention
IN1997DE01715A (fr) *	1997-06-24	2015-07-31	Council Scient Ind Res
US6545167B1 (en)	2002-04-04	2003-04-08	Fortune Bio-Tech Limited	Simple and effective manufacturing process for large scale recovery of Nimbin, a Neem seed constituent
US6866856B2 (en) *	2002-12-31	2005-03-15	Avon Products, Inc.	Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
JP2005206566A (ja) *	2004-01-26	2005-08-04	Iwamoto Shigemi	制癌予防食品
WO2007137386A1 (fr) *	2006-05-26	2007-12-06	Devarajan Anitha	Compositions et méthodes de traitement du vih/sida
WO2008004244A1 (fr) *	2006-07-05	2008-01-10	Hafiz Anwarul Aziz	Engrais sans produits chimiques
BRPI0701208A2 (pt) *	2007-03-26	2008-11-11	Wilton Viana	processo de obtenÇço de suplemento alimentar e produto assim obtido
BR102013021210B1 (pt)	2013-01-25	2015-12-01	Fundação Universidade Fed De São Carlos	processo de obtenção de nanopartículas biopoliméricas contendo óleo e extratos de azadirachta indica a. juss (neem), nanopartículas biopoliméricas e micropartículas em pó
WO2015035199A1 (fr) *	2013-09-06	2015-03-12	Mayo Foundation For Medical Education And Research	Compositions à base d'huile de neem utilisées pour traiter un cancer
US11324763B2 (en) *	2014-03-25	2022-05-10	National University Corporation Kagawa University	Malaria transmission prevention agent having rare sugar as effective component thereof and malarial parasite growth regulating agent
EP3586924A1 (fr)	2018-06-26	2020-01-01	Vorderwülbecke, Martin	Neem pour le traitement du syndrome des jambes sans repos
US11291647B2 (en)	2018-08-30	2022-04-05	Nisarga Biotech Private Limited	Process for preparation of CO2 extract of Azadirachta indica and herbal compositions thereof for treatment of cancers
EP4342482A1 (fr)	2022-09-23	2024-03-27	Laurenz Vorderwülbecke	Extrait de feuilles de neem arbre

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3132656C2 (de) *	1980-08-19	1986-09-04	Terumo Corp., Tokio/Tokyo	Extrakt aus der Rinde des Nim-Baumes (Melia azadirachta) mit antineoplastischer Wirkung
FR2488801B1 (fr) *	1980-08-19	1986-08-14	Terumo Corp	Extraits a l'eau chaude de l'ecorce du margousier, possedant une activite antineoplastique
DE3305047A1 (de) *	1982-02-19	1983-09-22	Terumo Kabushiki Kaisha trading as Terumo Corp., Tokyo	Polysaccharide, ihre herstellung und diese enthaltende therapeutische zusammensetzungen
US5196197A (en) *	1990-08-29	1993-03-23	National Institute Of Immunology	Reversible fertility control for prevention of pregnancy in females

1992
- 1992-09-11 US US07/944,201 patent/US5370873A/en not_active Expired - Fee Related
1993
- 1993-09-08 EP EP93921289A patent/EP0671925A4/fr not_active Withdrawn
- 1993-09-08 AU AU48440/93A patent/AU4844093A/en not_active Abandoned
- 1993-09-08 KR KR1019950700960A patent/KR950703348A/ko not_active Withdrawn
- 1993-09-08 CA CA002144320A patent/CA2144320A1/fr not_active Abandoned
- 1993-09-08 BR BR9307044A patent/BR9307044A/pt not_active Application Discontinuation
- 1993-09-08 JP JP6511477A patent/JPH08504403A/ja active Pending
- 1993-09-08 WO PCT/US1993/008240 patent/WO1994017815A1/fr not_active Ceased
1995
- 1995-03-10 OA OA60623A patent/OA10134A/en unknown

Also Published As

Publication number	Publication date
JPH08504403A (ja)	1996-05-14
BR9307044A (pt)	1999-06-29
US5370873A (en)	1994-12-06
CA2144320A1 (fr)	1994-08-18
EP0671925A4 (fr)	1996-02-28
KR950703348A (ko)	1995-09-20
WO1994017815A1 (fr)	1994-08-18
AU4844093A (en)	1994-08-29
EP0671925A1 (fr)	1995-09-20

Publication	Publication Date	Title
Molyneux et al.	2007	Phytochemicals: the good, the bad and the ugly?
OA10134A (en)	1996-12-18	Therapeutic compounds derived from the neem tree
Lopes et al.	1998	Flavonoids and lignans from Virola surinamensis twigs and their in vitro activity against Trypanosoma cruzi
EP0987024A2 (fr)	2000-03-22	Agents immunosuppresseurs
MX2011003940A (es)	2011-06-21	Proceso para extraer glucosidos cardiacos y composiciones.
US20080152736A1 (en)	2008-06-26	Lipid Fraction of Nigella Sativa L. Seeds
Prince et al.	1998	Effect of Syzigium cumini in plasma antioxidants on alloxan-induced diabetes in rats
AU2021469614A1 (en)	2024-05-02	Use of composition comprising astilbin and/or isomer thereof in preparation of drug for treating psoriasis
JP2002543140A (ja)	2002-12-17	免疫系の標的刺激へのフィランサスの使用
KR100516827B1 (ko)	2005-12-02	일산화질소생산억제제
Bergeron et al.	1996	Screening of plants used by North American Indians for antifungal, bactericidal, larvicidal and molluscicidal activities
Mohsin	2017	Evaluation of Phytochemical and Pharmacological Properties of Cichorium intybus (L) Based on Supercritical Fluid Extract.
Sreepriya et al.	2001	Protective effects of Indigofera tinctoria L. against D-galactosamine and carbon tetrachloride challenge on in situ perfused rat liver
CN109535115A (zh)	2019-03-29	了哥王中总香豆素类物质的提取方法及应用
Mir et al.	2021	Phytochemical isolation and anti-inflammatory properties of various extracts of Lilium polyphyllum
Garbi et al.	2017	In vitro anti-inflammatory properties of methanolic extract of Hibiscus sabdariffa flowers
Krishnaveni et al.	2011	Hepatoprotective effect of Moringa oleifera in isoniazid induced rats
KR100454087B1 (ko)	2004-11-02	항동맥경화 활성을 나타내는 틸리아닌
WO1998025639A1 (fr)	1998-06-18	AGENTS HYPOGLYCEMIANTS EXTRAITS DE HARUNGANA OU DE $i(VISMIA SPP.)
JP2005523301A (ja)	2005-08-04	Ｂａｒｌｅｒｉａｐｒｉｏｎｉｔｉｓｌｉｎｎからの抽出物を含む製薬組成物、およびその調製方法
KR100516560B1 (ko)	2005-09-22	혈당강하 및 진통제 조성물
Okokon et al.	2025	Antimalarial activities of Alchornea laxiflora stembark extract and fractions in Plasmodium berghei-infected mice
CN119818586A (zh)	2025-04-15	龙葵果来源纳米囊泡在制备预防和/或治疗前列腺癌药物中的应用
KR100247565B1 (ko)	2000-04-01	지모추출물을 유효성분으로 함유하는 면역억제제
Ross	2001	Laurus nobilis